A preference trial with rizatriptan 10 mg and ibuprofen 400 mg in migraine patients in the general practice

Trial Profile

A preference trial with rizatriptan 10 mg and ibuprofen 400 mg in migraine patients in the general practice

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2011

At a glance

  • Drugs Ibuprofen; Rizatriptan
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Jun 2011 Results presented at the 15th Congress of the International Headache Society.
    • 14 Sep 2009 Planned end date 9 Nov 2006 added as reported by Netherlands Trial Register record.
    • 10 Sep 2009 Planned number of patients (35) added, additional trial sponsor Reckitt benckiser added as reported by Netherlands Trial Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top